Kymera Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO Kymera Therapeutics is Nello Mainolfi, benoemd in Jun2019, heeft een ambtstermijn van 5.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 9.67M, bestaande uit 6.6% salaris en 93.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1% van de aandelen van het bedrijf, ter waarde $ 30.20M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 3.9 jaar.
Belangrijke informatie
Nello Mainolfi
Algemeen directeur
US$9.7m
Totale compensatie
| Percentage CEO-salaris | 6.6% |
| Dienstverband CEO | 5.4yrs |
| Eigendom CEO | 1.0% |
| Management gemiddelde ambtstermijn | 3.5yrs |
| Gemiddelde ambtstermijn bestuur | 3.9yrs |
Recente managementupdates
Recent updates
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 04
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
Oct 06Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up
Jul 14Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being
Jun 12We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth
May 03Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$167m |
| Jun 30 2024 | n/a | n/a | -US$158m |
| Mar 31 2024 | n/a | n/a | -US$155m |
| Dec 31 2023 | US$10m | US$640k | -US$147m |
| Sep 30 2023 | n/a | n/a | -US$167m |
| Jun 30 2023 | n/a | n/a | -US$158m |
| Mar 31 2023 | n/a | n/a | -US$159m |
| Dec 31 2022 | US$7m | US$600k | -US$155m |
| Sep 30 2022 | n/a | n/a | -US$154m |
| Jun 30 2022 | n/a | n/a | -US$139m |
| Mar 31 2022 | n/a | n/a | -US$124m |
| Dec 31 2021 | US$12m | US$571k | -US$100m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$58m |
| Mar 31 2021 | n/a | n/a | -US$48m |
| Dec 31 2020 | US$4m | US$454k | -US$55m |
| Sep 30 2020 | n/a | n/a | -US$53m |
| Jun 30 2020 | n/a | n/a | -US$57m |
| Mar 31 2020 | n/a | n/a | -US$52m |
| Dec 31 2019 | US$2m | US$362k | -US$41m |
Compensatie versus markt: De totale vergoeding ($USD 9.67M ) Nello } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.65M ).
Compensatie versus inkomsten: De vergoeding van Nello is gestegen terwijl het bedrijf verliesgevend is.
CEO
Nello Mainolfi (45 yo)
5.4yrs
Tenure
US$9,670,542
Compensatie
Dr. Nello Mainolfi, M.D., Ph D., is Co-Founder, President, Chief Executive Officer and Director at Kymera Therapeutics, Inc. since November 2019. Previously, at Kymera Therapeutics, Dr. Mainolfi served as...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 9.2yrs | US$266.46k | 0% $ 0 | |
| Co-Founder | 5.4yrs | US$9.67m | 1% $ 30.2m | |
| Chief Financial Officer | 5.3yrs | US$4.16m | 0.18% $ 5.4m | |
| Chief Operating Officer | 1.5yrs | US$5.19m | 0.0089% $ 267.6k | |
| Chief Legal Officer & Corporate Secretary | 1.8yrs | US$4.97m | 0.0094% $ 282.6k | |
| Chief Medical Officer | 6.2yrs | US$3.47m | 0.084% $ 2.5m | |
| Head of People & Culture | 2.5yrs | geen gegevens | geen gegevens | |
| Head of Research | 3.5yrs | geen gegevens | geen gegevens |
3.5yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van KYMR wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 9.2yrs | US$266.46k | 0% $ 0 | |
| Co-Founder | 5yrs | US$9.67m | 1% $ 30.2m | |
| Independent Director | 2.8yrs | US$236.46k | 0% $ 0 | |
| Lead Independent Director | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 3.7yrs | US$246.46k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$246.46k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$241.46k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$243.96k | 0% $ 0 | |
| Independent Director | 2yrs | US$231.46k | 0% $ 0 | |
| Independent Director | 4.7yrs | US$236.46k | 0% $ 0 |
3.9yrs
Gemiddelde duur
51.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van KYMR wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).